Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

BACKGROUND: Most patients with KIT-mutant gastrointestinal stromal tumours (GISTs) benefit from imatinib, but treatment resistance results from outgrowth of heterogeneous subclones with KIT secondary mutations. Once resistance emerges, targeting KIT with tyrosine kinase inhibitors (TKIs) sunitinib a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Serrano, César, Mariño-Enríquez, Adrián, Tao, Derrick L., Ketzer, Julia, Eilers, Grant, Zhu, Meijun, Yu, Channing, Mannan, Aristotle M., Rubin, Brian P., Demetri, George D., Raut, Chandrajit P., Presnell, Ajia, McKinley, Arin, Heinrich, Michael C., Czaplinski, Jeffrey T., Sicinska, Ewa, Bauer, Sebastian, George, Suzanne, Fletcher, Jonathan A.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6462042/
https://ncbi.nlm.nih.gov/pubmed/30792533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0389-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados